News
IDIBELL researcher takes part in sequencing the genome of chronic lymphocytic leukemia
IDIBELL researcher at Catalan Institute of Oncology (ICO) Silvia de Sanjosé has taken part in sequencing the genome of chronic lymphocytic leukemia. The research, led by the researcher of the Institute of Biomedical Research August Pi i Sunyer (IDIBAPS) Elias Campo, is published in the latest issue of the journal Nature. The results of this […]
Christian Dobel: ”aphasic patients can recover language abilities through the mechanisms that allow children to learn to speak”
Patients with aphasia (loss of ability to understand or produce language) are able to recover language skills through the same mechanisms that allow children to learn to speak. Complex activity About Dobel
Fundación Hesperia funds an IDIBELL research project on rare diseases
The Princes of Asturias receive the recipients of the aids in the Palacio de la Zarzuela The research group of neurometabolic diseases of IDIBELL led by the ICREA researcher Aurora Pujol will receive a grant of 45,000 euros for a research project on X -linked adrenoleukodystrophy.
Gianluigi Giannelli: ‘Stop cancer is not enough, we should stop dugs’ side effects too’
The researcher Gianluigi Giannelli of the University of Bari, Italy, focuses its research on studying the molecular mechanisms responsible for the progression of tumors, especially hepatic ones, and the identification of new therapeutic targets. Giannelli explained at a conference in the framework of the seminars IDIBELL, on 20 May that this must be the correct […]
IDIBELL researchers identified a new gene associated with risk of breast cancer
An international study led by researchers at the Institute of Biomedical Research of Bellvitge (IDIBELL) has identified a new gene involved in susceptibility of developing breast cancer. Article’s reference Evidence for a link between TNFRSF11A and risk of Breast Cancer.
Discovered a new mechanism to reduce cell growth and to induce programmed cell death of liver tumor cells
IDIBELL researchers demonstrate for the first time that inhibition of NADPH oxidases pathway slows the growth of tumor cells in vitro A study realized by researchers at the IDIBEL has shown that a drug that is under evaluation for cardiovascular disease, VAS2870, inhibits in vitro the enzymes of the family of NADPH oxidases in liver tumor cells. So it is able to reduce cell growth and regain the ability of the cell to self-destruct (apoptosis) in response to TGF-beta factor. The study results were published at the journal Biochemical Pharmacology. NADPH oxidases Article reference
Francisco Fernández Avilés: “We would end up with the shortage of donors and the problems of transplant rejection”
Cardiac regeneration could lead us to create bio-artificial hearts obtained from decellularized hearts and recomposed again with adult stem cells. This is the aim of the researcher and chief of cardiology at the Hospital Gregorio Maranon, Madrid, Francisco Fernández Avilés, who explained their latest advances in a new session of the seminars of IDIBELL on 13 May.
Live the Summer in IDIBELL
IDIBELL offers 12 positions for students to complete their formation during the summer months